Original Investigation

Human Genetics

, Volume 117, Issue 5, pp 485-493

First online:

DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein–Taybi syndrome (RSTS) and in another patient with incomplete RSTS

  • Oliver BartschAffiliated withInstitut für Humangenetik, Klinikum, Universität MainzInstitut für Klinische Genetik, Medizinische Fakultät, Technische Universität Dresden Email author 
  • , Stefanie SchmidtAffiliated withInstitut für Klinische Genetik, Medizinische Fakultät, Technische Universität Dresden
  • , Marion RichterAffiliated withInstitut für Klinische Genetik, Medizinische Fakultät, Technische Universität Dresden
  • , Susanne MorlotAffiliated withHumangenetische Praxis
  • , Eva SeemanováAffiliated withInstitute of Medical Biology and Genetics, 2nd Medical School, Charles University
  • , Glenis WiebeAffiliated withMax Planck Institute of Molecular Cell Biology and Genetics
  • , Sasan RasiAffiliated withInstitut für Klinische Genetik, Medizinische Fakultät, Technische Universität Dresden

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Rubinstein–Taybi syndrome (RSTS) is a distinct dominant disorder characterized by short stature, typical face, broad angulated thumbs and halluces, and mental retardation. The RSTS can be caused by chromosomal microdeletions and molecular mutations in the CREBBP gene; however, relatively few mutations have been reported to date. Here, we aimed to determine the rate of point mutations and other small molecular lesions in true RSTS and possible mild variants, by using genomic DNA sequencing. A consecutive series of patients including 17 patients from our previous study was investigated. We identified 19 causative mutations of CREBBP in a total of 45 patients representing three different diagnostic groups: (a) 17 mutations in 30 patients with unequivocal RSTS (detection rate 56.6%), (b) two mutations in eight patients with features suggestive of RSTS (“moderate or incomplete RSTS”, detection rate 25%), and (c) no mutation in seven patients with undiagnosed syndromes and isolated features of RSTS. In general, the mutations were distributed without hot spots and most were unique; however, three recurrent mutations (R370X, R1664H, and N1978S) were identified. Furthermore, we detected 15 different intragenic polymorphisms, including two non-synonymous coding polymorphisms, L551I and Q2208H. We report not only the highest detection rate (56.6%) of CREBBP mutations in patients with RSTS to date, but also the second missense mutation (N1978S) in a patient with moderate or incomplete RSTS. Previous studies have identified cytogenetic deletions in the CREBBP gene in eight to 12% of patients and very recently, Roelfsema et al. reported EP300 gene mutations in three of 92 (3.3%) patients with either true RSTS or different syndromes resembling RSTS. Our 56.6% detection rate of molecular mutations in CREBBP in patients with unequivocal RSTS supports the new concept that RSTS is a genetically heterogeneous disorder and furthermore, indicates that RSTS may be caused by gene/s other than CREBBP in up to 30% of cases.


CREB binding protein Rubinstein–Taybi syndrome Small molecular mutations